Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Arbutus Biopharma Corporation (ABUS) had Income from Continuous Operations of $-69.92M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$6.17M |
|
$-69.92M |
|
-- |
|
$6.17M |
|
$82.49M |
|
$-76.32M |
|
$6.40M |
|
$-69.92M |
|
$-69.92M |
|
$-69.92M |
|
|
Income from Continuous Operations |
$-69.92M |
$-69.92M |
|
$-69.92M |
|
$-76.32M |
|
$-74.94M |
|
185.61M |
|
185.61M |
|
$-0.38 |
|
$-0.38 |
|
| Balance Sheet Financials | |
$127.32M |
|
$3.31M |
|
$4.39M |
|
$131.71M |
|
$15.62M |
|
$2.86M |
|
$18.72M |
|
$34.34M |
|
$97.37M |
|
$97.37M |
|
$97.37M |
|
189.96M |
|
| Cash Flow Statement Financials | |
$-64.85M |
|
$22.95M |
|
$52.00M |
|
$26.29M |
|
$36.33M |
|
$10.04M |
|
$8.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.15 |
|
-- |
|
-- |
|
0.03 |
|
0.03 |
|
100.00% |
|
-1236.74% |
|
-1236.74% |
|
-1214.37% |
|
-1133.04% |
|
-1133.04% |
|
$-65.03M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
2.56 |
|
142.49 |
|
-71.81% |
|
-71.81% |
|
-53.09% |
|
-69.76% |
|
$0.51 |
|
$-0.35 |
|
$-0.35 |
|